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Abstract
Introduction: Diagnosis and management of Parkinson's disease (PD) rely heavily on evaluation
of clinical symptoms and patients' subjective perception of their condition. The purpose of this
study was to evaluate the validity, acceptability, and reliability of the Estonian version of the 39-
question Parkinson 's disease Questionnaire (PDQ-39).
Methods: Study subjects were approached during their regular clinic follow-up visits. 104 patients
consented to the study and 81 completed questionnaires were used for subsequent testing of
psychometric characteristics, validity and reliability.
Results: The content validity was assessed through qualitative content analysis during the pilot
study. The patients indicated that the questions were relevant to measure the quality of life of
people with PD.
The analysis of means showed that the ceiling and floor effects of domain results were within the
limits of 15% of Summary Index and of all domains except Stigma, Social Support and
Communication where the ceiling effect was 16% to 24% of the responses. Convergent validity was
interpreted through correlation between disease severity and PDQ-39 domains. There was a
statistically significant difference between the domain scores in patients with mild versus moderate
PD in domains of Mobility, ADL, and Communication but not for Stigma, Social Support and
Cognition. The reliability was good, Cronbach alpha for all domains and summary index was over
0.8 and item-test correlations between domains and summary index ranged from 0.56 to 0.83.
Conclusion:  The psychometric characteristics of an Estonian version of the PDQ-39 were
satisfactory. The results of this study were comparable to the results of previous validation studies
in other cultural settings in UK, USA, Canada, Spain and Italy.
The Estonian version of the PDQ-39 is an acceptable, valid and reliable instrument for quality of 
life measurement in PD patients.
Introduction
Parkinson's disease (PD) is a progressive neurodegenera-
tive disorder, characterised by bradykinesia, tremor, dis-
turbances of postural reflexes and of the autonomic
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nervous system, and which is most prevalent in old age [1-
3].
Diagnosis and management of PD is based on clinical
assessment of symptoms and signs using disease specific
rating scales [4,5]. Evaluation of disease severity, effect of
treatment procedures and interventions are all influenced
by the patient's perception of their disease and assessment
instruments have to take this aspect into account [4-6].
Such instruments measuring different factors affecting
patient's perception of well-being in relation to disease
and health are referred to as health related quality of life
(HRQOL) questionnaires. Measures of general HRQOL,
like the SF-36 [7,8] are used widely but are less suited to
assessment and management of a specific health condi-
tion compared to their disease specific counterparts, like
the 39-question Parkinson's Disease Questionnaire
(PDQ-39) [9].
The PDQ-39 has been translated into many languages all
over the world and extensively used for PD research by
many authors [10-13]. Translation and validation of an
instrument is a prerequisite for its use in a new cultural
context and only after validation is it possible to compare
the research data in a cross-cultural context [14,15].
The authors hypothesized the Estonian version PDQ-39
to be an acceptable, valid and reliable measure for use in
PD patients in Estonia and the aim of current study was to
test these hypotheses.
Methods
Questionnaire translation
The PDQ-39 consists of 39 questions, distributed between
eight multi-item domains: Mobility – ten questions; Activ-
ities of Daily Living – six questions; Emotional Well-being
– six questions; Stigma – four questions; Social Support –
three questions; Cognition – four questions; Communica-
tion – three questions; Bodily Discomfort – three ques-
tions. Responses to all questions are coded and mapped to
a percentage scale where 0 denotes "no problem" and 100
"maximum level of problem". Finally domain scores are
generated by calculating a simple average over all domain
item scores [6,9].
The translation procedure in our study took into account
different guidelines, recommendations and examples pre-
viously published on translation and cultural adaptation
of quality of life measures [11-16]. The procedure com-
prised forward translation, assessment of item compre-
hension, back translation to English and development of
a consensual version based on the results of previous
translations and comprehension assessments. First, for-
ward translation of the original PDQ-39 was independ-
ently carried out by two native Estonian speakers with
excellent knowledge of English. Reconciliation of these
two translations was then performed, followed by back
translation into English by a third translator without
access to the original version of PDQ-39. Comparison of
the back-translation and original versions of the question-
naire was performed and the results were used for the
development of the final consensual translation of the
Estonian language PDQ-39. Distance conversion into the
metric system was performed as a part of the translation
process when questionnaire items involved such measure-
ments.
Patients
The study included pilot-testing of the final Estonian ver-
sion of the PDQ-39 using a group of 15 PD patients from
the Tartu Parkinson's Disease Society [17]. All the patients
had first-hand knowledge of PD and agreed to comment
on the understandability and relevance of the question-
naire items during a group interview based on focus group
methodology. Descriptive figures on the group composi-
tion are given in the Table 1.
Table 1: Comparison of the characteristics of responders and non-responders
Pilot study for qualitative assessment Main study for psychometric statistical analysis
n = 15 Responders n = 81 Non-responders n = 23
Female/male (N) 9/6 55/26 10/11
Mean age, years (SD) 71.4 (8.9) 66.9 (8.2) 72.3 (7.4)
Age range 64–86 48–85 52–86
Duration of disease, years (SD) 7.8 (10.3) 8.9 (6.3) 7.5 (9.3)
Range 1–34 1–35 1–36
Treatment with levodopa (N of patients) 11 74 18
Combination antiparkinsonian medications (N of patients) 12 48 4
Adverse effects (dyskinesias, fluctuations etc) (N of 
patients)
12 44 4
Severity of disease HY I–II 5 48 15
HY III 7 29 7
HY IV–V 3 4 1Health and Quality of Life Outcomes 2008, 6:23 http://www.hqlo.com/content/6/1/23
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The main study involved 108 patients with a previous
diagnosis of idiopathic PD who were approached during
their regular follow-up visits to the neurological out-
patient clinic of the Department of Neurology and Neuro-
surgery of the University of Tartu which is one of the two
tertiary healthcare providers in Estonia. Patient recruit-
ment was also carried out in 5 regional secondary level
out-patient centres (out of 8) during 1999–2001 for a ran-
dom mix of complex and regular cases. All patients con-
sented to initial medical examination by the first author.
Patients satisfying the criteria of the UK PD Society Brain
Bank [18] and scoring over 25 points (out of 30) on cog-
nitive function testing using the Mini Mental State Exam-
ination (MMSE) [19] were proposed to take part in the
study. One hundred and four patients satisfied the inclu-
sion criteria, completed informed consent forms and were
enrolled into the study.
Disease severity assessment was performed during the
recruitment visit, using the Unified Parkinson's Disease
Rating Scale (UPDRS version 3.1) and Hoehn and Yahr
(HY) staging system [4,5]. All assessments of cognitive
ability and disease severity were conducted when the
patient's health status was stable and PD was in the 'on'
period. Patients were grouped by severity of disease as fol-
lows: mild (HY stages I–II), moderate (HY III) and severe
disease (HY IV–V). Disease grouping was used in order to
estimate the correlation between clinical stages and PDQ-
39 domains for assessment of convergent validity.
Co-morbidities were ascertained using medical records
(e.g. depression was recorded as a co-morbid condition in
case medical records included indications of depression,
sleep disorder or antidepressant prescription). In addi-
tion, current medications for both PD and other diseases
along with treatment side effects were recorded during the
first examination.
PDQ-39 questionnaires were handed to study subjects at
the end of their recruitment visit for self-reporting in their
usual environment. The collection period for returned
questionnaires was 4 weeks. Second copies of PDQ-39
(responses of which were not used for other psychometric
tests) were mailed to all patients two weeks after the recep-
tion of the first questionnaire. The PDQ-39 was accompa-
nied by a checklist on health status change during these
two weeks. This test-retest was carried out to assess the
reproducibility of the PDQ-39 results.
Acceptability, validity and reliability
The psychometric analysis of the Estonian version of the
PDQ-39 was performed by evaluation of acceptability,
validity, and reliability of the questionnaire using qualita-
tive content analysis and a variety of statistical procedures.
All PDQ-39 domains and general health status data were
checked for floor and ceiling effects and less than 15% of
minimum or maximum values per domain were consid-
ered acceptable [20]. Skewness and kurtosis were calcu-
lated to ascertain normal distribution of the data.
Background data were analysed using univariate methods
and ANOVA. The Kruskal-Wallis test was applied to com-
pare the distribution of mean scores of the domains of
PDQ-39.
Content validity of the questionnaire was tested during
the pilot-testing of the PDQ-39 translation. Group discus-
sion and interviews followed completion of the question-
naire regarding how easy it was to understand, whether it
measured quality of life and how relevant it was.
Construct validity was assessed by comparing PDQ-39
domain scores by the HY stages using ANOVA statistics.
Cronbach alpha greater than 0.7 was considered a strong
indication of questionnaire reliability. Item-total correla-
tions over 0,4 were considered to show acceptable corre-
lation between the questionnaire items. Spearman rank
correlation was used to show item-item correlations.
Reproducibility was tested using test-retest analysis and a
correlation of 0.7 or more determined an adequate result.
All test results with an error level of 5% or less (p ≤ 0.05)
were considered statistically significant.
Results
Psychometric analysis was conducted in two groups of
patients: 15 patients in the pilot study for processing the
qualitative assessment of the questionnaire and 104
patients in the main study group, for which 81 self-
reported questionnaires were completed and used in the
statistical analysis, a response rate of 79%. The PD
patients who entered the final analysis group were catego-
rised by severity of disease as follows: 48 patients (59%)
in mild stage (HY stage I–II), 29 patients (36%) in mod-
erate stage (HY III) and 4 patients (5%) in severe stage
(HY IV–V). Non-responders belonged to mild (16
patients) and moderate (5 patients) disease groups while
two disease severity assessment questionnaires were unus-
able. Descriptive characteristics of the responders and
non-responders are shown in Table 1.
The most frequently reported concomitant diseases were
high blood pressure (24%), coronary heart disease (24%),
and joint disease (14%). There were two cases of stroke
and one of malignancy among the patients in the severe
disease group. The majority (60%) of patients lived in an
urban area. The most common medication was levodopa
and all patients with severe PD suffered from adverse
effects of their medications.Health and Quality of Life Outcomes 2008, 6:23 http://www.hqlo.com/content/6/1/23
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Validity interpretation was carried out using the ability of
the PDQ-39 to distinguish high and low symptom burden
and correlation of questionnaire responses to clinically
assessed severity of PD. The patients in mild stages of PD
had an average summary index score 35.8, for patients in
a moderate stage of disease it was 46.1 and for patients in
an advanced stage of the disease it was 59.1 (Figure 1).
There was a statistically significant difference between the
domain scores in patients with mild versus moderate PD
for the domains of Mobility, ADL, and Communication.
The difference in scores for Stigma, Social support and
Cognition was not significant.
Content validity was assessed through the qualitative con-
tent analysis during the pilot study. All the questions and
domains were essential to PD patients for measurement of
quality of life.
Internal consistency for all domains was good as the
Cronbach alpha measure was above 0.7 in all cases (rang-
ing from 0.81 to 0.86) indicating good reliability of the
questionnaire (see details in Table 2). Item-test correla-
tions for all questions and domains ranged from 0.56 to
0.83 again confirming the consistency of the question-
naire (only domain figures are given in Table 2 for the
sake of brevity). The item-item correlations of mean
domain scores were moderate ranging from 0.67 between
Mobility and Activities of Daily Living to 0.2 between
Communication and Bodily Discomfort (Table 3) as
expected.
Mean scores and standard errors of PDQ-39 domains by Hoehn and Yahr stages of illness Figure 1
Mean scores and standard errors of PDQ-39 domains by Hoehn and Yahr stages of illness. 
ADL-Activities of Daily Living; Emot w-b - Emotional Well-being; Soc Sup - Social Support; Cogn - Cognition; Comm - Com-
munication; Bodily Dis -  Bodily Discomfort; SI – Summary Index.  
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Table 2: Internal consistency (Cronbach alpha) and item-test 
correlations between mean domain scores and the summary 
index score of the PDQ-39 (n = 81).
Domain Cronbach alpha Item-test correlation
Mobility 0.85 0.69
Activities of daily living 0.85 0.72
Emotional well-being 0.85 0.83
Stigma 0.86 0.72
Social support 0.84 0.68
Cognition 0.82 0.67
Communication 0.83 0.56
Bodily discomfort 0.81 0.69
All the coefficients were significant (p < 0.05).Health and Quality of Life Outcomes 2008, 6:23 http://www.hqlo.com/content/6/1/23
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Reproducibility of the results and test-retest reliability of
the questionnaire were assessed by correlation between
results of test and retest questionnaires from a selection of
patients. These results ranged from 0.72 to 0.92 indicating
good reproducibility. The retest number of responders
was 78.
The whole range of possible scores (0–100) of the PDQ-
39 domains were covered. The mean and median were
very similar in the domains of Mobility, Activity of Daily
Living (ADL), Emotional Well-Being and Stigma, with a
difference of less than 10%. For Cognition, the difference
was 16%. The difference between the mean and median
for the summary index was approximately 1% (see Table
4 for details).
The floor effect ranged from 1.2% to 2.5% in the domains
of Mobility, ADL, Emotional Well-being, Cognition and
Bodily Discomfort, while for the domains of Stigma,
Social Support and Communication it ranged from 16%
to 24%, which was more than hypothesized. It is also
noteworthy that among patients with moderate or severe
PD patients the response distribution was more central
and the only floor effect was recorded for the Social Sup-
port domain (21% compared to the 25% in the mild PD
group). The lowest ceiling effects (1.2%) were observed in
Mobility, ADL, Emotional Well-Being, Social Support and
Communication domains. In other domains the ceiling
effect was between 2.4% to 3.7%. The criterion of ceiling
effects below 15% was achieved in all domains. Both ceil-
ing and floor effects of the Summary index (SI) were at the
1.2% level. The analyses showed that the distribution of
the results in the domains and summary index was within
the limits of the preset criteria in most cases.
Discussion
This paper presented the evidence on acceptability, valid-
ity and reliability of the Estonian version of the PDQ-39
which were good as originally hypothesised. The descrip-
tive statistics for the acceptability assessment of the ques-
tionnaire showed a good distribution of the response
choices on the scale level, ceiling and floor effects were
low and within hypothesized limits with only few excep-
tions. Content and face validity tests unambiguously
showed that the covered topics and items in the translated
PDQ-39 questionnaire are relevant to the Estonian PD
patients. Validity assessment of the Estonian version of
the PDQ-39 was guided by experience from previous sim-
ilar studies [6,21-25] and as expected the localised version
of PDQ-39 was able to differentiate between disease
groups with the lowest and highest PD burden. Most of
the previous validation studies in other cultural settings
[9-16] have used a variety of rating scales and classifica-
tions like Hoehn and Yahr stages, UPDRS scores and main
symptoms for assessment of construct validity. All these
studies found statistically significant differences between
Table 3: Spearman rank correlation between domains and summary index (SI) of the Estonian version PDQ-39.
Mobility ADL Emot w-b Stigma Soc supp Cogn Comm Bodily dis
Mobility
Activities of daily living (ADL) 0.67
Emotional well-being (Emot w-b) 0.51 0.45
Stigma 0.30 0.37 0.57
Social support (Soc supp) 0.32 0.37 0.66 0.53
Cognition (Cogn) 0.43 0.49 0.49 0.29 0.35
Communication (Comm) 0.32 0.32 0.25 0.28 0.26 0.43
Bodily discomfort (Bodily dis) 0.34 0.34 0.61 0.43 0.52 0.42 0.20
Summary index (SI) 0.81 0.79 0.8 0.62 0.66 0.64 0.64 0.46
Table 4: Mean, standard deviation (SD) median scores, 95% confidence interval, skewness and kurtosis of domains of the PDQ-39 
Estonian version (n = 81).
Domain Mean SD Median 95% Confidence interval Skewness Kurtosis
Mobility 46.7 26.1 47.5 40.9 – 52.5 0.1 2.3
Activities of daily living 44.1 25.1 41.7 38.5 – 49.6 0.3 2.1
Emotional well-being 39.8 25.0 37.5 34.3 – 45.3 0.3 2.1
Stigma 34.2 28.3 31.3 27.9 – 40.3 0.5 2.2
Social support 27.6 24.5 25.0 22.1 – 32.9 0.8 3.3
Cognition 35.2 21.8 41.7 37.4 – 46.4 0.1 2.2
Communication 30.6 20.8 33.3 25.9 – 35.2 0.3 3.1
Bodily discomfort 45.3 22.5 50.0 40.3 – 50.3 0.1 2.0
Summary index 39.0 17.7 38.6 36.7 – 44.6 0.1 2.4Health and Quality of Life Outcomes 2008, 6:23 http://www.hqlo.com/content/6/1/23
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disease severity and PDQ-39 domains as an example for
the domains of Mobility and Activities of Daily Living
(mean scores ranging from 22.34 (HY I) to 75.25 (HY IV–
V) [6,22,24,25] which ranged from 36.5 (HY I–II) to 90.5
(HY IV–V) in our study. The differences of the domains of
Stigma, Social support, Emotional Well-Being and Bodily
discomfort were not so clearly related to the severity of PD
stages. The summary index scores were the lowest in the
patient group with mild PD and highest in the severe dis-
ease group as expected to once more indicating close psy-
chometric values to other language versions of PDQ-39
[11,12,22]. The somewhat worse domain scores especially
in the case of Mobility and Activities of Daily living could
be related to the still developing social care system in Esto-
nia but verification of this assumption would recuire a
direct comparison of country situations and respective
social care systems.
Regarding the reliability and other internal consistency
measures the strongest correlations between domain and
total questionnaire score have been found for the
domains of mobility and Activities of Daily Living [9-16].
These two domains showed strong item-test correlations
in our study as well. The reliability figures of Estonian ver-
sion of PDQ-39 surpassed the results from cross-cultural
studies from USA, Canada, Spain, Italy and Japan [10] as
witnessed by Cronbach alpha above 0.80 [26] for all
domains compared to a wider range (from 0.13 to 0.96)
in those studies. The lowest Cronbach alpha coefficients
in those studies were found in Japan and seemed to be
connected to that particular cultural background [10].
Test-retest analysis showed no differences of score distri-
butions between the two assessments as no changes were
recorded in previous reports of the original version of
PDQ-39 [15,22,24]. The localisation of PDQ-39 to Esto-
nian context was successful since all preset criteria were
met and the results of this study were comparable to the
results of previous validation studies in other cultural set-
tings in UK, USA, Canada, Spain and Italy.
One of the possible drawbacks of the current study is asso-
ciated with the relatively small sample size. However, dur-
ing the study planning a relative size of the study group
was set at 5% of the total PD population in Estonia and
that target was reached with the current sample. Also, the
mean age of the patients in the sample corresponded well
to the mean age of the overall PD population in Estonia
[27]. Especially good representativeness of the Estonian
PD population was achieved for the patient groups with
mild and moderate disease. However, the patient group
with severe PD had better response rate than the group
with mild PD as 4 out of 5 patients did return a filled
questionnaire. The PDQ-39 is a self-administered written
questionnaire and the study inclusion criteria therefore
were set to include only patients having the ability to per-
form that particular task. The small number of patients
with severe PD available for validation of written PDQ-39
highlighted the need for a HRQL measure in Estonia that
could be administered in an interview form to the severe
patients of PD.
The analysis of sample variation and statistical signifi-
cance testing showed that albeit the possible drawbacks
related to the sample size and composition the Estonian
language version of PDQ-39 performed well in the psy-
chometric testing. Therefore, the use of PDQ-39 is highly
warranted for disease assessment and treatment manage-
ment among the PD patients able to administer the ques-
tionnaire as the localised version of the PDQ-39 is a valid
and reliable tool in this setting.
Conclusion
The Estonian version of the PDQ-39 demonstrated similar
validity and reliability to the original English language
version.
It is an acceptable, valid and reliable instrument to meas-
ure quality of life of PD patients in future studies in Esto-
nia.
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